SCHEMBL2740951

SCHEMBL2740951

O=[N+]([O-])c1ccc(N/N=C/c2cc(Cl)cc(Cl)c2O)c(S(=O)(=O)Nc2ccccc2Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 12/20 0.57
▸ KMT2A Q03164 12/20 0.57
▸ MAPT P10636 12/20 0.57
▸ NPC1 O15118 7/20 0.57
▸ GAA P10253 6/20 0.57
▸ HTT P42858 6/20 0.57
▸ RAB9A P51151 6/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.57
▸ XBP1 P17861 1/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.55
▸ PLA2G1B P04054 1/20 0.54
▸ ATG4B Q9Y4P1 1/20 0.54
▸ PSMD14 O00487 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.51
▸ GLA P06280 1/20 0.51
▸ TLR9 Q9NR96 1/20 0.51
▸ KDM4E B2RXH2 3/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ TNNI3 P19429 1/20 0.47
▸ TNNT2 P45379 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741006 0.86 MEN1 (0.55) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740990 0.84 L3MBTL1 (0.57) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2741013 0.83 MEN1 (0.58) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2741007 0.83 MEN1 (0.58) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740986 0.80 MEN1 (0.56) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740948 0.80 L3MBTL1 (0.55) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740993 0.80 MAPT (0.55) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740987 0.80 MEN1 (0.55) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740988 0.80 PLA2G1B (0.64) MEN1KMT2AMAPTNPC1GAA
SCHEMBL2740949 0.79 MEN1 (0.54) MEN1KMT2AMAPTNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 MEN1 1381/4885KMT2A 217/4885MAPT 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback